Tesnatilimab

Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD)[1][2].

[1] Kasper Vadstrup, et al. Anti-NKG2D mAb: A New Treatment for Crohn's Disease Int J Mol Sci. 2017 Sep 16;18(9):1997. DOI:10.3390/ijms18091997
[2] Wei L, et al. The role of NKG2D and its ligands in autoimmune diseases: new targets for immunotherapy[J]. International Journal of Molecular Sciences, 2023, 24(24): 17545. DOI:10.3390/ijms242417545